Scope and claims analysis for US Drug Patent 10,835,517 (lotilaner or fluralaner eye drops for Demodex blepharitis and ocular Demodex infestations)
US 10,835,517 is directed to topical, sterile, non-irritating ophthalmic eye-drop treatment of human ocular Demodex conditions using an isoxazoline parasiticide where lotilaner or fluralaner is the isoxazoline and where the isoxazoline parasiticide is the sole active ingredient. Claim scope is anchored on (i) ocular-route dosing to the ocular surface and/or periocular tissues, (ii) formulation constraints (sterile, non-irritating, eye-drop; no tea tree oil; sole active isoxazoline), and (iii) treatment-use endpoints tied to Demodex infestation/phenotypes, including blepharitis and rosacea-associated disease. Dependent claim fallbacks narrow to specific concentration ranges, dosing volumes, dosing frequency and duration, Meibomian gland contact mechanics, and adjunctcastor oil.
What is US Patent 10,835,517 and what does it claim (independent-claim scope)?
Independent claim 1: method for Demodex blepharitis via sterile, non-irritating isoxazoline ophthalmic eye drop
Claim 1 is a “method of treating” claim with a tightly constrained composition-and-use packet. It requires all of the following elements:
- Patient and disease: “one or more eyes of a human patient in need of treatment” of Demodex blepharitis.
- Administration route and target: topically administering directly to an ocular surface of one or more eyes.
- Active: an isoxazoline parasiticide.
- Formulation: “formulated into an ophthalmic composition” that is:
- sterile and non-irritating to the eye
- an eye drop
- has a pharmaceutically acceptable vehicle
- Exclusion: ophthalmic composition does not comprise tea tree oil.
- Sole active constraint: isoxazoline parasiticide is the sole active ingredient of the ophthalmic composition.
- Isoxazoline identity: the isoxazoline comprises lotilaner or fluralaner.
- Local therapeutic limitation: composition is “only locally therapeutically effective” (local ocular/periocular effect, not systemic therapeutic effect).
This is not a broad “any Demodex treatment” claim. It is a narrow “lotilaner or fluralaner eye-drop regimen” defined by sterility, non-irritation, eye-drop delivery, the “sole active” requirement, and a specific negative ingredient (no tea tree oil).
Independent claim 6: method for Demodex blepharitis with eyelids/eyelashes as dosing target
Claim 6 tracks claim 1 but shifts the administration target from ocular surface to a broader periocular treatment zone:
- Topically administering directly to: one or more of the eye, eyelids, or eyelashes.
- Composition constraints stay the same: eye drop, sterile, non-irritating, pharmaceutically acceptable vehicle, sole active isoxazoline, no tea tree oil, and lotilaner or fluralaner as the isoxazoline.
Claim 6 therefore covers techniques where the product is applied to eyelashes/eyelids such that eyelash follicles and periocular structures receive therapeutic contact, not just conjunctiva/cornea contact.
Independent claim 13: method for ocular Demodex infestation (broader than blepharitis)
Claim 13 is a broader disease framing:
- Treating “an ocular Demodex infestation”
- Using the same formulation packet: topical eye-drop, sterile/non-irritating, sole active isoxazoline, no tea tree oil, lotilaner or fluralaner.
- Target is still “ocular surface of one or more eyes.”
Claim 13 then depends into multiple ocular Demodex phenotypes (blepharitis, ocular rosacea, MGD, conjunctivitis, keratitis).
Independent claim 22: method for ocular Demodex infestation (claims 13 variant with minimal target differences)
Claim 22 is essentially the same formulation-constrained ocular Demodex infestation method as claim 13, with dependent claims narrowing into blepharitis/rosacea/MGD/conjunctivitis and with a dependent identity claim on lotilaner.
How do the dependent claims narrow product composition, concentration, dosing, and contact mechanics?
Concentration and dosing strength narrowing
- Claim 2: isoxazoline concentration < 0.50% by weight of total composition.
- Claim 3: isoxazoline concentration 0.15% to 0.40% by weight.
- Claim 10: in the claim set that follows claim 6, isoxazoline concentration 0.001% to 1% by weight.
These dependent claims matter for designing around by selecting concentrations outside the recited ranges. They also create litigation handles for claim construction on whether “by weight of the total weight of the composition” includes excipients, suspended particles, and whether the active exists as a pure active vs. salt/form.
Ocular-surface location narrowing
- Claim 4: ocular surface comprises at least one of conjunctiva or cornea.
This anchors claim scope even within “ocular surface” to core anatomy.
Excipients and ingredient exclusions
- Claim 5: ophthalmic composition comprises castor oil.
Castor oil is a key positive excipient limitation. From a design-around perspective, inclusion or exclusion can decide whether this dependent claim is met, assuming the independent claim is already met.
- Independent claims include negative limitation: ophthalmic composition does not comprise tea tree oil. No dependent claim relaxes that; it remains an express exclusion for every method claim.
Periocular delivery mechanics
- Claim 7: in claim 6, eyes are closed upon topically administering, so composition contacts Meibomian gland orifices and outside eyelid margins.
- Claim 8: further spreading onto eyelashes and follicles.
- Claim 9: spreading with an applicator.
These are not just “where” but “how applied.” They can be used to distinguish between simple drop instillation vs. application intended to reach gland orifices and lash follicles.
Dosage volume and treatment cadence
- Claim 16: dose volume 25 to 50 microliters of the eye drop administered at least once daily (in the ocular Demodex infestation method set).
- Claims 11 and 12: at least once daily for:
- ≥ 2 weeks (claim 11)
- ≥ 4 weeks (claim 12)
These dependent parameters create additional potential carve-outs for shorter regimens, different volumes, or less-than-once-daily schedules.
Assessment-triggered treatment algorithm
- Claim 14: receiving a first assessment of quantity of Demodex mites on an anatomical structure, and administering only if the quantity is greater than a predetermined value.
This converts the method into a decision-and-treatment protocol rather than a universal regimen.
Mechanistic wording tied to mite movement
- Claim 15: composition causes “abdomen and tail” of Demodex mites to stop moving more quickly relative to “cephalothorax.”
This provides an unusual pharmacodynamic endpoint. It can influence validity and infringement fights by anchoring the claims to a measurable observation on mite segments.
Specific ocular Demodex phenotypes covered
From the ocular Demodex infestation set (claims 17-21 and 24-27), the following disease descriptors are recited:
- Blepharitis
- Ocular rosacea
- Meibomian gland dysfunction
- Conjunctivitis
- Keratitis
These dependent claims can broaden commercial coverage because they support labeling-style disease narratives, even if the core formulation packet remains the same.
Isoxazoline identity dependent claim
- Claim 28: isoxazoline is lotilaner.
So the patent estate includes at least one route where “fluralaner” is not sufficient to practice the specific dependent claim (assuming lotilaner is a distinct and separable identity).
What does the “sole active ingredient” and “does not comprise tea tree oil” requirement do to freedom to operate?
Sole active ingredient constraint
Claim language makes the ophthalmic composition meet the “sole active ingredient” requirement. For infringement risk, a competitor that adds any additional active ingredient (even an approved ocular therapeutic active) can avoid meeting this limitation, unless the added agent is argued not to be an “active ingredient” under claim construction.
Tea tree oil exclusion
The “does not comprise tea tree oil” limitation provides a categorical design-around lever. A formulation containing tea tree oil would, by its presence, fall outside the recited scope of the method claims.
In practice, this negative limitation becomes a key litigation issue because manufacturers sometimes use botanical components in vehicles. The factual question is whether the product “comprises tea tree oil” as an ingredient.
Claim construction pressure points likely to matter in litigation
-
“Ophthalmic composition is sterile and non-irritating”
- “Sterile” implicates manufacturing and testing.
- “Non-irritating” can become a functional limitation requiring evidence of lack of irritation in ocular use conditions.
-
“Only locally therapeutically effective”
- Creates a local vs. systemic effect distinction.
- The standard of proof in infringement may hinge on pharmacokinetic/toxicology evidence and therapeutic effect boundaries.
-
“Directly” topically administering
- Competing products could argue indirect application if contact is mediated by devices or applicators that do not “directly” apply to ocular surface or periocular structures.
-
“Eye drop” vs. other ophthalmic formats
- A formulation delivered as gel, ointment, spray, or slow-release insert could be argued outside “eye drop,” depending on how the term is construed.
-
Isoxazoline parasiticide identity and form
- Claims require lotilaner or fluralaner. Prodrugs, salts, polymorphs, or stereoisomer mixtures may raise whether they are still the claimed isoxazoline parasiticide.
How many different claim “modes” exist inside US 10,835,517?
At least four infringement pathways are embedded:
- Demodex blepharitis targeting ocular surface (claim 1)
- Demodex blepharitis targeting eye/eyelids/eyelashes (claim 6 and its dependent contact and mechanics claims 7-9)
- Ocular Demodex infestation targeting ocular surface (claim 13 and its dependent disease/algorithm/volume/movement claims 14-16 and 17-21)
- Ocular Demodex infestation targeting ocular surface (claim 22 plus lotilaner identity via claim 28 and disease phenotypes via claims 24-27)
Because all modes share the same composition packet, a single “core formulation” is the center of the estate. The rest is route/contact/dosing phenotyping.
Patent landscape implications for competitors
Primary strategic vulnerability: product formulation vs. method-of-use
Because the claims repeatedly tie to an eye-drop composition with:
- sole active isoxazoline
- no tea tree oil
- sterile/non-irritating
- local therapeutic effectiveness
a competitor’s easiest design-arounds are typically formulation-level:
- introduce a different active (breaking “sole active”), or
- include tea tree oil (breaking “does not comprise”), or
- shift from “eye drop” format, or
- change to a non-isoxazoline active.
If the competitor stays within lotilaner/fluralaner as sole active and uses an eye-drop route, the remaining opportunities are mostly method parameters:
- dosing volume outside 25-50 microliters (for those dependent claim sets),
- treatment duration outside ≥2 weeks or ≥4 weeks,
- avoid eyelid/Meibomian orifices contact mechanics required by claim 7,
- avoid the assessment-triggered algorithm.
Where infringement risk is highest
Infringement risk concentrates on products that:
- use lotilaner or fluralaner as the only active,
- are sold/used as sterile ophthalmic eye drops,
- do not include tea tree oil,
- target Demodex blepharitis or ocular Demodex phenotypes,
- and have dosing regimens within the dependent ranges.
Where infringement risk can be reduced
Risk drops where a product:
- adds any additional active ingredient,
- includes tea tree oil,
- uses a non-eye-drop ocular dosage form,
- or uses an isoxazoline not covered by “lotilaner or fluralaner.”
Key takeaways
- US 10,835,517 is a composition-constrained method-of-treatment patent centered on lotilaner or fluralaner eye-drop therapy for human ocular Demodex (including Demodex blepharitis and related ocular phenotypes).
- Independent claims require sterile, non-irritating ophthalmic eye-drop with pharmaceutically acceptable vehicle, where the isoxazoline is the sole active ingredient and the formulation does not comprise tea tree oil, and where the therapy is only locally therapeutically effective.
- Dependent claims tighten infringement exposure via concentration ranges, castor oil inclusion, conjunctiva/cornea targeting, eyelid/eyelash/Meibomian gland orifice contact mechanics, dose volumes (25-50 µL), treatment duration (≥2 weeks or ≥4 weeks), and an assessment-triggered regimen.
- For freedom-to-operate, the most direct carve-outs are formulation-level (breaking “sole active” or including tea tree oil) and dosage-form-level (“eye drop” vs alternatives). Method-level changes (contact mechanics, volumes, duration) can also reduce risk but usually only as to the narrower dependent-claim pathways.
FAQs
- Does “sole active ingredient” allow inert antimicrobial preservatives or pH adjusters in the claimed composition?
- If a competitor adds an additional approved ocular active (for example, anti-inflammatory), does that avoid the “sole active isoxazoline” limitation?
- How much do the claim 7 eyelids-closed and Meibomian orifice contact mechanics narrow infringement coverage compared with claim 1 ocular-surface administration?
- Can dosing outside 25-50 microliters avoid infringement of the ocular Demodex infestation dependent claims without changing the core formulation?
- If a product contains tea tree oil as a minor component, does it fall entirely outside the method claims even if it uses lotilaner/fluralaner eye-drop?
References
- US Patent No. 10,835,517 (claims provided in prompt).
